当前位置: X-MOL 学术Mol. Med. Rep. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Rab6c is a new target of miR‑218 that can promote the progression of bladder cancer.
Molecular Medicine Reports ( IF 3.4 ) Pub Date : 2021-09-13 , DOI: 10.3892/mmr.2021.12432
Long He 1 , Xiang Pan 1 , Xialu Wang 2 , Yuhua Cao 3 , Peng Chen 4 , Cheng Du 5 , Daifa Huang 3
Affiliation  

Bladder cancer has high morbidity and mortality rates among the male genitourinary system tumor types. MicroRNA‑218 (miR‑218) is associated with the development of a variety of cancer types, including bladder cancer. Rab6c is a member of the Rab family and is involved in drug resistance in MCF7 cells. The aim of the present study was to clarify the relationship between Rab6c and miR‑218 in bladder cancer cell lines. In this study, the expression levels of miR‑218 and Rab6c were evaluated via reverse transcription‑quantitative PCR and western blotting, respectively. The association between Rab6c and miR‑218 was recognized via TargetScan analysis and dual luciferase reporter gene detection. Cell proliferation was analyzed using Cell Counting Kit‑8 and colony formation assays, and the invasive ability was measured via Transwell assays. Rab6c was highly expressed in bladder cancer, while miR‑218 had abnormally low expression in bladder cancer. In addition, there was a mutual regulation between Rab6c and miR‑218 in bladder cancer. It was found that overexpression of Rab6c significantly enhanced the proliferation, colony formation and invasion of T24 and EJ cells. Furthermore, miR‑218 overexpression blocked the promoting effects of Rab6c on the malignant behavior of bladder cancer cells. Thus, Rab6c promotes the proliferation and invasion of bladder cancer cells, while miR‑218 has the opposite effect, which may provide a novel insight for the treatment of bladder cancer.

中文翻译:

Rab6c 是 miR-218 的一个新靶点,可以促进膀胱癌的进展。

膀胱癌在男性泌尿生殖系统肿瘤类型中具有较高的发病率和死亡率。MicroRNA-218 (miR-218) 与多种癌症类型的发展有关,包括膀胱癌。Rab6c 是 Rab 家族的成员,参与 MCF7 细胞的耐药性。本研究的目的是阐明膀胱癌细胞系中 Rab6c 和 miR-218 之间的关系。在本研究中,分别通过逆转录定量 PCR 和蛋白质印迹评估了 miR-218 和 Rab6c 的表达水平。通过 TargetScan 分析和双荧光素酶报告基因检测识别 Rab6c 和 miR-218 之间的关联。使用 Cell Counting Kit-8 和集落形成分析分析细胞增殖,并通过 Transwell 分析测量侵袭能力。Rab6c 在膀胱癌中高表达,而 miR-218 在膀胱癌中异常低表达。此外,Rab6c 和 miR-218 在膀胱癌中存在相互调节作用。发现Rab6c的过表达显着增强了T24和EJ细胞的增殖、集落形成和侵袭。此外,miR-218过表达阻断了Rab6c对膀胱癌细胞恶性行为的促进作用。因此,Rab6c促进膀胱癌细胞的增殖和侵袭,而miR-218具有相反的作用,这可能为膀胱癌的治疗提供新的见解。发现Rab6c的过表达显着增强了T24和EJ细胞的增殖、集落形成和侵袭。此外,miR-218过表达阻断了Rab6c对膀胱癌细胞恶性行为的促进作用。因此,Rab6c促进膀胱癌细胞的增殖和侵袭,而miR-218具有相反的作用,这可能为膀胱癌的治疗提供新的见解。发现Rab6c的过表达显着增强了T24和EJ细胞的增殖、集落形成和侵袭。此外,miR-218过表达阻断了Rab6c对膀胱癌细胞恶性行为的促进作用。因此,Rab6c促进膀胱癌细胞的增殖和侵袭,而miR-218具有相反的作用,这可能为膀胱癌的治疗提供新的见解。
更新日期:2021-09-13
down
wechat
bug